Search results

2125 results

Sorted by Date . Sort by Relevance

  1. Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

    Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic (secondary) non-squamous non-small-cell lung cancer in adults after

  2. Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

    Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy

  3. Hysteroscopic sterilisation by insertion of intrafallopian implants (IPG587)

    October 2017: The device used in this procedure (Essure) no longer has a CE mark. The CE mark is necessary for medical devices to be used in EU countries. Therefore NICE has decided to suspend its guidance. NICE would consider whether to issue new guidance on “Hysteroscopic sterilisation by insertion of intrafallopian implants” should evidence including an appropriately CE marked device become available.

  4. Cystic fibrosis: diagnosis and management (NG78)

    This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.

  5. Immunosuppressive therapy for kidney transplant in children and young people (TA482)

    Evidence-based recommendations on immunosuppressive therapy for kidney transplant in children and young people

  6. Child abuse and neglect (NG76)

    This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.

  7. Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults

  8. Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)

    Evidence-based recommendations on autologous chondrocyte implantation (ACI) in people with symptomatic articular cartilage defects of the knee

  9. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease (IPG593)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease

  10. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by high spinal cord injuries (IPG594)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with high spinal cord

  11. Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

    Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults

  12. Intermediate care including reablement (NG74)

    This guideline covers referral and assessment for intermediate care and how to deliver the service. Intermediate care is a multidisciplinary service that helps people to be as independent as possible. It provides support and rehabilitation to people at risk of hospital admission or who have been in hospital. It aims to ensure people transfer from hospital to the community in a timely way and to prevent unnecessary admissions to hospitals and residential care.

  13. Ab externo canaloplasty for primary open-angle glaucoma (IPG591)

    Evidence-based recommendations on ab externo canaloplasty for primary open-angle glaucoma in adults. This involves widening the eye’s main draining canal by

  14. High-intensity focused ultrasound for symptomatic breast fibroadenoma (IPG592)

    Evidence-based recommendations on high-intensity focused ultrasound for symptomatic breast fibroadenoma in adults. This involves using high-frequency sound wave

  15. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults

  16. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab

  17. Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

    Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic PD-L1-positive non-small-cell lung cancer (NSCLC) in adults

  18. Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)

    Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel; Abraxane) for untreated metastatic pancreatic cancer in adults

  19. Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

    Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults

  20. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG590)

    Evidence-based recommendations on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer in adults. This involves

  21. Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

    Evidence-based recommendations on Holoclar for treating limbal stem cell deficiency in adults after eye burns

  22. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer

  23. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

    Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children

  24. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

    Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults

  25. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease (COPD) in adults with chronic bronchitis

  26. Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease (IPG585)

    Evidence-based recommendations on laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease in adults. This involves putting a

  27. Transcatheter aortic valve implantation for aortic stenosis (IPG586)

    Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for aortic stenosis. This involves inserting a new valve through a catheter

  28. Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

    Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults